RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial

Growth hormone (GH) replacement therapy usually requires daily subcutaneous (s.c.) injections that can be burdensome for patients and their caregivers. Somapacitan, a long-acting reversible albumin-binding GH derivative, is in development for once-weekly s.c. administration in children with GH defic...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Bradley, Blair, Joanne C, Højby Rasmussen, Michael, Böttcher, Volker, Juul Kildemoes, Rasmus, Maniatis, Aristides, Beck Bang, Rikke, Mori, Jun, Polak, Michel, Stagi, Stefano, Horikawa, Reiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625361/
http://dx.doi.org/10.1210/jendso/bvac150.1325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625361/
http://dx.doi.org/10.1210/jendso/bvac150.1325

Ejemplares similares